New therapy aims to ease spiritual distress in latino cancer patients
NCT ID NCT04015609
First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times
Summary
This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasibility and cultural relevance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Meaning Centered Psychotherapy for Latinos (MCP-L)
- What this could lead to
- If successful, this could provide a culturally tailored therapy to improve spiritual well-being and reduce distress in Latino patients with advanced cancer.
- What could go wrong
- This is an early feasibility study, so it is small and not designed to prove effectiveness. Results may not apply to all Latino populations or cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 177 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2015
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Phase I: Quantitative * Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients) * Age 18 or older * As per self report, Latino/a or Hispanic ethnicity * As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual) Phase 2: Qualitative * Enrolled in the quantitative phase of study (as seen above) * Completes the quantitative phase questionnaire package * Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3) * In the judgment of the investigator, willing and able to be interviewed in Spanish only * Agrees to be audio- recorded Phase 3: Provider Feedback * Professionals working in the mental health field; * Have a caseload of five or more Latino cancer patients per month * Able to communicate and read in Spanish * Agrees to be audio or video-recorded Phase 4: Patient Feedback * Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients) * Age 18 or older * As per self report, Latino/a or Hispanic ethnicity * In the judgment of the investigator, willing and able to be interviewed in Spanish only * Agrees to be audio-recorded Exclusion Criteria: Phase 1: Quantitative * In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection * In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible) Phase 2: Qualitative * In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection * In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible) Phase 4: Patient Feedback * Diagnosed with a major disabling medical or psychiatric condition * Unable to understand the consent procedure * Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lincoln Medical and Mental Health Center
RECRUITINGThe Bronx, New York, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Ponce Health Sciences University
RECRUITINGPonce, 00732, Puerto Rico
-
Ralph Lauren Center for Cancer Care and Prevention
RECRUITINGNew York, New York, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors